Patent ID: 8580252

Claim:
A pharmaceutical composition, comprising: a) a soluble neutral active human hyaluronidase glycoprotein (sHASEGP), wherein: the hyaluronidase glycoprotein is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the hyaluronidase polypeptide; the hyaluronidase polypeptide does not comprise the complete sequence of amino acids set forth in SEQ ID NO:1; and the hyaluronidase polypeptide consists of: (i) a sequence of amino acid residues contained within SEQ ID NO:1 that includes at least amino acids 36-464 of SEQ ID NO:1, wherein the polypeptide is truncated within the C-terminus of SEQ ID NO:1 at a C-terminal amino acid residue selected from among 467, 477, 478, 479, 480, 481, 482, 483 and 494 of SEQ ID NO:1; or (ii) a sequence of amino acid residues that has at least 95% amino acid sequence identity with a sequence of amino acids set forth in (i); and b) an anti-cancer agent selected from among Alemtuzumab, Bevacizumab, Docetaxel, Gemcitabine, Ibritumomab tiuxetan, Ortataxel, Paclitaxel, Rituximab, Tositumomab and Trastuzumab.